Gilead Sciences Inc (GIS.SG)

Compare

96.73

+0.05

+(0.05%)

As of 1:58:20 PM GMT+2. Market Open.

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks 23 hours ago

GILD
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues

Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.

Zacks 4 days ago

^GSPC

FME.DE

GILD
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.

Zacks 4 days ago

GILD

^GSPC
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.

Zacks 5 days ago

GILD

^GSPC
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 5 days ago

GILD
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Zacks 6 days ago

GILD
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 6 days ago

GLPG

GLPGF

PTCT
GILD or AMGN: Which Is the Better Value Stock Right Now?

GILD vs. AMGN: Which Stock Is the Better Value Option?

Zacks 6 days ago

AMGN

GILD
Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV

NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years ...

ACCESS Newswire 7 days ago

GILD
These biotech names aren't facing 'huge concern' from tariffs

Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 7 days ago

GILD

VRTX

AMGN
Moderna, biotech stocks slide following resignation of FDA official Peter Marks

The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.

Yahoo Finance 7 days ago

DVAX

PCVX

NVAX
1 Healthcare Stock to Target This Week and 2 to Turn Down

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.

StockStory 8 days ago

RVTY

GILD

JNJ
Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%

Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive human rights policy. The company advised voting against these proposals, slated for discussion at the upcoming annual meeting. Despite broader market challenges like the Dow's 1.7% decline and inflation concerns, Gilead's stock rose 18% over the last quarter, potentially buoyed by its robust Q4...

Simply Wall St. 10 days ago

GILD
High Growth Tech Stocks in the US Market

The United States market has remained flat over the past week but has shown an 8.5% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in capturing emerging opportunities within this dynamic sector.

Simply Wall St. 12 days ago

NCNO

FICO

GILD
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy rating on the shares with a $125 price target in a note Wednesday. With Gilead up 1.2% to $109.23 on Wednesday, the price target suggests potential upside of 14%.

Barrons.com 12 days ago

GILD
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

Zacks 12 days ago

GILD

ANGO
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer

NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients and their treatment. Now lessons learned from the ...

ACCESS Newswire 14 days ago

GILD
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.

Zacks 14 days ago

GILD

^GSPC
Trump Trade: President to sign EO on DOE, weighing Chevron license extension

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: DEPARTMENT OF EDUCATION: President Donald Trump is expected to sign an executive order Thursday to close the Education Department, fulfilling a yearslong pledge to dismantle the federal agency, the White House confirmed, report Garrett Haake, Nnamdi Egwuonwu and Tyler Kingkade of NBC News. Trump

TipRanks 17 days ago

AAPL

GILD

TSM
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.

StockStory 18 days ago

BMRN

GILD

MRNA

Performance Overview

Return	GIS.SG	S&P 500 (^GSPC)
YTD	+8.40%	-13.93%
1-Year	+57.44%	-2.69%
3-Year	+90.03%	+12.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gilead Sciences Inc (GIS.SG)

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Biotech stocks slide as Marks resignation seen being negative for sector

GILD or AMGN: Which Is the Better Value Stock Right Now?

Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV

These biotech names aren't facing 'huge concern' from tariffs

Moderna, biotech stocks slide following resignation of FDA official Peter Marks

1 Healthcare Stock to Target This Week and 2 to Turn Down

Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%

High Growth Tech Stocks in the US Market

Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

Trump Trade: President to sign EO on DOE, weighing Chevron license extension

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

Performance Overview